

## キーワード索引

### 第73巻 平成15年度

#### A

- abdominal CT scan .....(11) 476  
 accesorry parotid gland .....(12) 500  
 ACTH .....(11) 463  
 ACTH stimulation .....(11) 460, 470  
 acute hepatitis .....(5) 126  
 adrenal adenoma .....(11) 478  
 adrenal venous sampling (11) 463, 478, 481, 484, 487  
 adrenocortical hyperplasia .....(11) 484  
 adrenomedullin .....(12) 493  
 adult GHD .....(9・10) 405  
 adult-learning .....(5) 133  
 aldosterone to cortisol ratio .....(11) 470  
 aldosterone/cortisol ratio .....(11) 463  
 alpha-fetoprotein (AFP) .....(6) 194  
 angiogenesis .....(9・10) 399  
 angiotensin receptor antagonist (ARB) .....(1・2) 14  
 arthroscopic surgery .....(3・4) 65  
 asthmatic death .....(3・4) 110  
 autoimmune hepatitis .....(5) 126

#### B

- Billroth I reconstruction .....(11) 450  
 biochemical modulation chemotherapy .....(3・4) 99  
 bovine .....(3・4) 88  
 brain stem .....(6) 176  
 bronchial asthma treatment .....(3・4) 110

#### C

- cartilaginous degeneration .....(3・4) 65  
 cell infiltration .....(3・4) 71  
 cephalometric radiograms .....(12) 516  
 chemotherapy .....(3・4) 105  
 chloroquine .....(1・2) 1  
 chronic liver disease .....(7) 214  
 chronotherapy .....(11) 435

- cleavage .....(8) 245  
 clerkship director .....(5) 149  
 clinical clerkship .....(5) 149  
 clinical competence .....(5) 140  
 clinical course .....(5) 126  
 clinical criteria .....(5) 126  
 cognitive competence-levels .....(5) 133  
 complication .....(7) 242  
 confinement .....(9・10) 424  
 contrast-enhanced ultrasonography .....(1・2) 22  
 contrast sensitivity .....(7) 242  
 CPA (cardio pulmonary arrest) .....(3・4) 110  
 curriculum .....(5) 140  
 cutaneous pigmented lesion .....(11) 445

#### D

- dhfr/dhps* .....(1・2) 1  
 diagnosis .....(1・2) 22  
 distal gastrectomy .....(11) 450  
 dysmenorrhea .....(1・2) 51

#### E

- electric stimulation test .....(5) 117  
 ELISA .....(3・4) 71  
 endocrine hypertension .....(7) 205  
 endothelin .....(12) 493  
 endothelium .....(12) 493  
 ethanol .....(12) 508  
 evaluation .....(5) 140  
 excimer laser .....(7) 236, 242  
 extramammary Paget's cancer .....(3・4) 99

#### F

- faculty development .....(5) 133, 140, 149  
 fibrin glue .....(12) 508  
 Flt-1 .....(9・10) 399  
 fluid transport .....(9・10) 412

foreigner ..... (12) 526

## G

gallbladder carcinoma ..... (6) 194  
 GAS ..... (8) 245  
 gastric cancer ..... (11) 450  
 gastroduodenal ..... (12) 508  
 GIST ..... (3·4) 105, (7) 222  
 granulocyte and monocyte apheresis ..... (9·10) 419  
 granulocyte colony-stimulating factor (G-CSF) ..... (6) 194

## H

HBV ..... (12) 531  
 healthy carrier ..... (12) 531  
 heart disease ..... (6) 169  
 hematemesis ..... (7) 222  
 hemorrhagic ulcer ..... (12) 508  
 hemostasis with local injection ..... (12) 508  
 hepatic metastasis ..... (7) 226  
 hepatitis C virus (HCV) ..... (7) 214  
 hepatocellular carcinoma ..... (1·2) 22, 28, (7) 214  
 hippocampus ..... (5) 117  
 HOMA-R ..... (9·10) 405  
 home blood pressure ..... (11) 435  
 hypertension ..... (1·2) 14

## I

IgA nephropathy ..... (1·2) 14, (3·4) 71  
 IGF-I ..... (9·10) 405  
 IL-10 ..... (3·4) 78  
 IL-1 $\beta$  ..... (3·4) 78  
 imatinib ..... (3·4) 105  
 informed consent ..... (1·2) 35  
 innovational medical education ..... (5) 133  
 inoperable recurrent colorectal cancer ..... (6) 188  
 interstitial injury ..... (3·4) 71  
 intracorneal ring (ICR) ..... (7) 236  
 intussusception ..... (9·10) 429

## J

Japan ..... (1·2) 35

## K

KDR ..... (9·10) 399  
 knee joint ..... (3·4) 65

## L

L-selectin ..... (3·4) 71  
 laser ..... (11) 445  
 laser in situ keratomileusis (LASIK) ..... (7) 236, 242  
 Letton and Wilson method ..... (6) 200  
 leukocytosis ..... (6) 194  
 Levovist ..... (1·2) 22  
 liver tumor ..... (1·2) 22  
 local recurrence ..... (1·2) 28, (3·4) 99  
 low-dose 5-FU and cisplatin therapy ..... (6) 188  
 lymph-node metastasis ..... (3·4) 99

## M

Malawi ..... (1·2) 1  
 malignant lymphoma ..... (9·10) 429  
 mechanical stimulation ..... (6) 176  
 medial release ..... (3·4) 65  
 medical bill ..... (12) 526  
 medical education ..... (5) 149  
 medical suits ..... (1·2) 35  
 morning hypertension ..... (11) 435  
 morning versus evening (M/E) ratio ..... (11) 435  
 mouse ..... (3·4) 78  
 myopia ..... (7) 236

## N

natural course ..... (12) 531  
 NO ..... (12) 493  
 non-Hodgkin ..... (9·10) 429

**O**

- obesity ..... (7) 205  
 orphanin FQ/nociceptin ..... (6) 176  
 osteoarthritis ..... (3·4) 65

**P**

- pain ..... (6) 176  
 paired associative memory ..... (5) 117  
 pancreas injury ..... (6) 200  
 pancreas pseudocyst ..... (6) 200  
 pancreatitis ..... (3·4) 78  
 parotid gland enlargement ..... (12) 500  
 parotid gland surgery ..... (12) 500  
 parotid gland tumor ..... (12) 500  
 perioperative care ..... (9·10) 419  
 phakic IOL ..... (7) 236  
 PID (pelvic inflammatory disease) ..... (1·2) 51  
*Plasmodium falciparum* malaria ..... (1·2) 1  
 postmenopausal hypertension ..... (7) 205  
 postoperative quality of life ..... (11) 450  
 prednisolone ..... (5) 126  
 pregnancy ..... (7) 205  
 primary aldosteronism ..... (11) 460, 463, 470,  
                                  476, 478, 481, 484, 487  
 proteinuria ..... (1·2) 14

**Q**

- QOL (quality of life) ..... (6) 169

**R**

- radiofrequency ablation ..... (1·2) 28  
 randomized controlled trial ..... (11) 435  
 rectal GIST ..... (7) 226  
 rectal smooth muscle sarcoma ..... (7) 226  
 refractive surgery ..... (1·2) 35  
 regular steroid inhalation therapy ..... (3·4) 110  
 renal pathology ..... (1·2) 14  
 reticular formation ..... (6) 176  
 risk factor ..... (7) 214

- risk management ..... (3·4) 110  
 rupture of the main pancreas duct ..... (6) 200

**S**

- salivary gland disease ..... (12) 500  
 secondary amenorrhea ..... (1·2) 51  
 selective adrenal sampling ..... (11) 460  
 selective adrenal venous sampling ..... (11) 470  
 selective amygdalo-hippocampectomy ..... (5) 117  
 self-directed learning ..... (5) 133  
 seroconversion ..... (12) 531  
 severe trismus ..... (9·10) 424  
 SF36 ..... (6) 169  
 skin cooling ..... (11) 445  
 small intestine ..... (9·10) 429  
 social support ..... (6) 169  
 somatopause ..... (9·10) 405  
 STD (sexuality transmitted disease) ..... (1·2) 51  
 STI571 ..... (3·4) 105  
 stomach ..... (3·4) 105  
 streptococcal pyrogenic exotoxin-B ..... (8) 245  
 streptococcal toxic shock syndrome ..... (8) 245  
 streptococcus ..... (3·4) 88  
 streptolysin O ..... (8) 245  
 subclinical hepatitis ..... (12) 531  
 sulfadoxine/pyrimethamine ..... (1·2) 1  
 superantigen ..... (3·4) 88  
 super-long pulsed vascular laser ..... (11) 445  
 surgical treatment ..... (9·10) 429  
 synthetic chloride channel ..... (9·10) 412

**T**

- T cell ..... (3·4) 88  
 taxonomy ..... (5) 140  
 teenage pregnancy ..... (1·2) 51  
 temporal lobe epilepsy ..... (5) 117  
 the oral and maxillofacial area ..... (12) 516  
 The United States ..... (1·2) 35  
 TNF $\alpha$  ..... (3·4) 78  
 traumatic myositis ossificans ..... (9·10) 424  
 Traveler Law ..... (12) 526  
 treatment ..... (1·2) 28

type IV collagen 7S .....( 7 ) 214

**U**

ulcerative colitis .....(9·10) 419

urinary 18-hydroxycortisol .....(11) 463

urotensin II .....(12) 493

**V**

vascular endothelial growth factor .....(9·10) 399

**W**

Williams syndrome .....(12) 516

work shop .....( 5 ) 149